Sanofi Healthcare gets marketing authorisation for cGVHD drug

Sanofi Healthcare India has obtained marketing authorization for Rezurock, a drug for treating Chronic graft versus host disease (cGVHD), a condition that occurs after allogeneic stem cell transplants. The drug, approved by USFDA and CDSCO, offers a new treatment option for patients over 12 years old after other treatments have failed.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/XPnaIYR
via IFTTT